Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2016-12-01 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于召开2016年第四次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2016 fourth extraordinary general meeting of shareholders for 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It includes information about the meeting date, voting methods (onsite and online), agenda items to be discussed and voted on (such as changes to registered capital, amendments to the articles of association, and use of idle raised funds), registration procedures for shareholders, and detailed instructions for proxy voting and online voting. The document does not contain financial statements or results but is a formal notice to shareholders about the meeting and how to participate and vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is over 5,000 characters and contains substantive meeting and voting information, not just a brief announcement or a report publication notice. Therefore, the correct classification is PSI with high confidence.
2016-12-01 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company (贝达药业股份有限公司) regarding abnormal stock trading fluctuations. It details the situation of unusual trading volume, the company's investigation and confirmation that no undisclosed material information exists, and a risk warning to investors. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a regulatory announcement related to stock trading behavior and risk disclosure. The document length is 4260 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-11-27 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a company (贝达药业股份有限公司) regarding abnormal stock price fluctuations over two trading days. It includes detailed explanations and risk factors related to the stock price movements, confirms no undisclosed material information, and reminds investors of risks. The document is titled as a "股票交易异常波动公告" which translates to "Stock Trading Abnormal Fluctuation Announcement." It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report like an Annual Report or Interim Report, nor is it a voting result or a regulatory filing about compliance. It is a specific announcement about stock price abnormality and related disclosures, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2016-11-24 Chinese
关于召开2016年第四次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2016 fourth extraordinary general meeting of shareholders for Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, agenda items for shareholder voting, registration procedures, voting methods (both in-person and online), and related attachments such as proxy forms and voting instructions. The document does not contain financial statements, audit results, earnings data, or management discussion. It is not a report but a formal announcement and notification to shareholders about the meeting and voting process. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or the actual voting results, it is best classified as Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is not a brief announcement but a detailed solicitation document for shareholder voting.
2016-11-22 Chinese
关于签署募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for raised funds by the company 贝达药业股份有限公司. It details the amount of funds raised through an IPO, the opening of special accounts for these funds, and the supervisory roles of involved parties. The document references regulatory approvals and an audit report but does not contain the audit report itself or detailed financial statements. The content focuses on the management and supervision of capital raised, which aligns with updates on company fundraising and capital structure changes. The document length is 2370 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2016-11-22 Chinese
独立董事关于第二届董事会第五次会议相关事项发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of Betta Pharmaceuticals Co., Ltd. regarding specific matters discussed at the company's second board of directors' fifth meeting. It focuses on the use of raised funds to replace self-raised funds invested in projects and the use of idle raised funds for cash management. The document references compliance with regulatory guidelines and audit reports but does not contain financial statements or comprehensive financial data. It is a governance-related opinion on board meeting matters rather than a full report or announcement of voting results. The document length is short (1487 characters), and it is not an announcement of a report publication but an independent directors' opinion on board matters. Therefore, the best fitting category is Board/Management Information (MANG).
2016-11-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.